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Summary
Background: Chronic fatigue syndrome (CFS) is rela-
tively common and disabling. Over 8000 patients
attend adult services each year, yet little is known
about the outcome of patients attending NHS
services.
Aim: Investigate the outcome of patients with CFS
and what factors predict outcome.
Design: Longitudinal patient cohort.
Methods: We used data from six CFS/ME (myalgic
encephalomyelitis) specialist services to measure
changes in fatigue (Chalder Fatigue Scale), physical
function (SF-36), anxiety and depression (Hospital
Anxiety and Depression Scale) and pain (visual ana-
logue pain rating scale) between clinical assessment
and 8–20 months of follow-up. We used multivari-
able linear regression to investigate baseline factors
associated with outcomes at follow-up.
Results: Baseline data obtained at clinical assess-
ment were available for 1643 patients, of whom
834 (51%) had complete follow-up data. There
were improvements in fatigue [mean difference
from assessment to outcome: 6.8; 95% confidence
interval (CI) 7.4 to 6.2; P<0.001]; physical func-
tion (4.4; 95% CI 3.0–5.8; P<0.001), anxiety (0.6;
95% CI 0.9 to 0.3; P<0.001), depression (1.6;
95% CI 1.9 to 1.4; P<0.001) and pain (5.3;
95% CI 7.0 to 3.6; P<0.001). Worse fatigue,
physical function and pain at clinical assessment
predicted a worse outcome for fatigue at follow-up.
Older age, increased pain and physical function at
assessment were associated with poorer physical
function at follow-up.
Conclusions: Patients who attend NHS specialist
CFS/ME services can expect similar improvements
in fatigue, anxiety and depression to participants
receiving cognitive behavioural therapy and
graded exercise therapy in a recent trial, but are
likely to experience less improvement in physical
function. Outcomes were predicted by fatigue, dis-
ability and pain at assessment.
! The Author 2013. Published by Oxford University Press on behalf of the Association of Physicians.
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Introduction
Chronic fatigue syndrome (CFS), also known as
myalgic encephalomyelitis (ME), is defined as per-
sistent or recurrent debilitating fatigue that is not
lifelong, not the result of ongoing exertion, not alle-
viated by rest, not explained by other conditions and
results in a substantial reduction in function.1–3 CFS
is heterogeneous4 and relatively common, with an
estimated prevalence from population surveys of be-
tween 0.2% and 2.6% depending on case definition
and recruitment methodology.5–10 Adults with CFS
can be very disabled11 and are generally unwell for
a long time, with a median duration of illness of 6.3
years.12
Over 8000 adults13 are assessed and treated by
specialist UK National Health Service (NHS) CFS/
ME clinical teams each year and although we
have trial evidence about which treatments are ef-
fective, little is known about what happens when
patients are treated in the NHS setting or which fac-
tors are associated with treatment outcomes. One
previous study showed that outcomes were better
for patients with CFS enrolled in a trial of cognitive
behavioural therapy (CBT; N=30) when compared
with those receiving CBT as part of everyday clinical
practice.14 The only other service evaluation we
found showed that secondary care outpatients who
received CBT improved their function and symptom
count, although only 61% gave follow-up data.15
There is clear trial evidence that CBT and graded
exercise therapy (GET), are moderately effective for
the treatment of CFS.16,17 In a recent trial, CBT and
GET were each associated with a mean improve-
ment of 7 points on the Chalder Fatigue Scale,
comparing baseline with 52 weeks follow-up and
19 points on the SF-36 physical function
subscale17.
NHS specialist CFS/ME services in England follow
National Institute for Health and Clinical Excellence
(NICE) guidelines, offering CBT or GET, or compo-
nents of CBT or GET alone or with activity manage-
ment and sleep management.3 For severely affected
patients, the guidelines recommend an activity man-
agement programme that draws on the principles of
CBT and GET.3
In this study, we use data from the CFS/ME
National Outcomes Database (NOD) to investigate:
(i) what the prognosis is for patients accessing NHS
specialist services; (ii) which routinely collected
baseline measures predict post-treatment outcomes
(fatigue, physical function, pain and mood) and (iii)
whether outcomes are similar to those recorded in
the Pacing, graded Activity and Cognitive Beha-
vioural Therapy: a randomised Evaluation (PACE)
trial for CBT and GET (the most effective treatments).
Methods
Study population
We included patients who had attended one of six
NHS specialist CFS/ME services during the period 1
January 2005 to 31 December 2009. The six ser-
vices were chosen because they had been collecting
12-month outcome data for at least 1 year during the
study period and had achieved >40% 12-month
follow-up. Patients were included if they were age
18 years or older and were diagnosed with CFS
according to Centers for Disease Control criteria.1,2
Services treated patients with CBT, GET, a combin-
ation of both or activity management, in group and/
or individual treatment sessions of varying numbers
and lengths.
Patient-level data
In each of the six services, patients routinely com-
pleted the following inventories prior to their initial
clinical assessment (baseline): 11-item Chalder
Fatigue Scale;18 10-item SF-36 physical function
subscale;19 14-item Hospital Anxiety and
Depression Scale (HADS);20 and a Visual Analogue
Pain Rating Scale (score of 0 for ‘no pain’ and 100
for ‘pain as bad as possible’). The Chalder Fatigue
Scale was scored using the 0–3 method for scoring
each question (0 ‘Less than usual’, 1 ‘No more than
usual’, 2 ‘More than usual’ and 3 ‘Much more than
usual’). On the physical function subscale of the
SF-36 (RAND version), patients scored 0 (‘Yes, lim-
ited a lot’) 5 (‘Yes, limited a little’) or 10 (‘No, not
limited at all’) for each question, (range 0–100 with
0 being most disabled). Inventory total scores (and
each HADS subscale score) were coded as missing if
more than one question was unanswered; if only
one item was missing, an adjusted total score was
calculated. The same set of inventories was sent to
patients by post 12 months after their initial clin-
ical assessment. Patients were asked at assessment
to report the duration of their illness (time elapsed,
in months, between onset of symptoms and clinical
assessment). Data on treatments received by each
patient are not currently recorded in the NOD.
Service-level data
Information was collected from specialist services
using a self-completed questionnaire which
included questions on: numbers of patients assessed
per annum; total number of staff employed (full-time
equivalent); type of treatments offered (CBT, GET,
activity management); number of treatment sessions
the service usually offered/aimed to offer; ratio of
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group/individual sessions and estimated average
contact time with patients.
Follow-up interval
Each team sent out follow-up questionnaires at 12
months. Variation in when the questionnaires were
sent and delays in return of 12-month follow-up
questionnaires led to variation in the exact time of
follow-up. Also, some teams obtained data at add-
itional follow-up points (e.g. 6 and 24 months). To
maximize the availability of follow-up data for our
analysis, we determined a margin of follow-up
either side of 12 months. We did this by fitting frac-
tional polynomial generalized estimating equation
(GEE) regression models of fatigue against
time.21,22 This method (implemented in Stata as frac-
poly combined with xtgee) compares a linear GEE
model with the best-fitting first and second degree
models, each containing fractional polynomial
terms (from a pre-defined set of integer, fractional
and negative powers) for time. The differences in
deviances between the linear and 1st-degree model
and the first and second degree models are tested
using a chi-squared test and the resulting P-values
indicate whether the change in outcome over time is
linear or whether it has a more complex shape. We
inspected a plot of predicted values of fatigue
against time from the model with the best fit to de-
termine an appropriate follow-up interval in which
observed fatigue scores could be assumed to be rep-
resentative of the scores predicted at 12 months. In
patients with more than one follow-up assessment,
the closest to 12 months was used.
Statistical analysis
Our primary outcome measures were fatigue and
physical function. Our secondary outcome meas-
ures were anxiety, depression and pain. We used
chi-squared tests (10-year age group and sex) and
Kruskal–Wallis tests (duration of illness, fatigue,
physical function, anxiety, depression and pain) to
compare the baseline characteristics of patients for
whom we had/did not have complete follow-up data
on primary and secondary outcomes. We defined
clinically useful improvements within each person
as having a difference of 2 points on the total
Chalder Fatigue Scale and a difference of 11
points on the SF-36 physical function subscale
between the baseline and follow-up measurements.
We chose these cut-offs because they equated to 0.5
SD of the distribution of the baseline measurements.
These characteristics were included in a random
effects linear regression model, with service as a
unit of random effect, to identify factors
measured at baseline that were independently
associated with outcomes measured in the
follow-up interval. Scores from the different inven-
tories were re-scaled, for this particular analysis, so
that the range for each was 0–10 so that a regres-
sion coefficient of 1 represents a 10% change in the
score.
Ethical approval
The North Somerset and South Bristol Research
Ethics Committee decided that the collection and
analysis of CFS/ME patient data were part of service
evaluation and as such did not require ethical
review by a NHS Research Ethics Committee or ap-
proval by NHS Research and Development offices
(REC reference number 07/Q2006/48).
Results
Patients and follow-up
Complete baseline data were available for 1643
patients assessed by the six services during the
study period. Of these patients, 1269 (77.2%) were
female, the mean age was 39.9 (12.6 SD) years, and
patients had been ill for a median of 36 months
[interquartile range (IQR) 16–84] before accessing
a service. Follow-up data on fatigue were available
for 53.7% (882 of 1643) patients up to 24 months
after assessment. The median interval between as-
sessment and follow-up was 375 (IQR: 357–402)
days. We fitted a fractional polynomial model to
these data to determine the interval that represented
a reasonably steady state of fatigue around 12
months after assessment. The model with the best
fit incorporated a term for ˇtime. Fatigue was rela-
tively constant between 8 and 20 months (240–600
days) after assessment (Figure 1). Hence, we used
this interval to capture the maximum amount of
follow-up data.
Of the 1643 patients with complete baseline data,
834 (50.8%) had complete (fatigue, physical func-
tion, anxiety, depression and pain) follow-up data
between 8 and 20 months after assessment. We
compared patients with and without complete
follow-up data (Table 1). Patients without follow-up
data were slightly younger than patients with
follow-up data [mean age 38.5 (12.4 SD) years vs.
41.3 (12.7 SD) years, Student’s t-test P<0.001] but
were similar in all other characteristics.
At follow-up, there were improvements in fatigue,
SF-36 physical function, anxiety, depression and
pain (Table 2). About 74% (620 of 834) of patients
had a decreased Chalder Fatigue score at follow-up
and 64% (534 of 834) had improved by >2 points
(our definition of a clinically useful improvement). In
Outcomes of treatment of chronic fatigue syndrome in England 557
contrast, only 50% (416 of 834) of patients had an
increased SF-36 physical function score at follow-up
and only 16% (131 of 834) had improved by >22
points. In total, 14% (120 of 834) had clinically
useful improvements on both scales.
Patient-level factors associated with
treatment outcomes
There was strong evidence (P<0.001) that each
baseline measure (fatigue, physical function,
Figure 1. Predicted values of fatigue against time from generalized estimating equation regression model incorporating a
fractional term for time (time) (N=882). Vertical lines indicate follow-up interval adopted for this study (8–20 months).
Table 1 Characteristics of CFS patients with and without follow-up data
Characteristics Without follow-up
data (N=809)
With follow-up
data (N=834)
P-valuea
Age (years) median (IQR) 38 (28–47) 41 (32-51) <0.001
Female N (%) 617 (76.3) 652 (78.2) 0.36
Duration of illness (months) median (IQR) 36 (17–96) 36 (15–84) 0.06
Chalder Fatigue (0–33) median (IQR) 27 (23–30) 28 (23–30) 0.22
SF-36 physical (scale 0–100) median (IQR) 40 (20–60) 40 (25–55) 0.46
Anxiety (scale 0–21) median (IQR) 10 (7–14) 10 (7–13) 0.30
Depression (scale 0–21) median (IQR) 9 (7–12) 9 (7–12) 0.92
VPain (scale 0–100) median (IQR) 52 (24–70) 51 (24–69) 0.52
aChi-squared test for categorical variables; Kruskal–Wallis test for continuous variables
Table 2 Characteristics of CFS patients at baseline and at follow-up (N=834)
Characteristics Baseline Follow-up Mean Difference P-valuea
mean (SD) mean (SD) (95% CI)
Chalder Fatigue (0–33) 26.5 (5.2) 19.7 (8.4) 6.8 (7.4 to 6.2) <0.001
SF-36 physical function (scale 0–100) 40.6 (22.7) 45.0 (27.2) 4.4 (3.0 to 5.8) <0.001
HADS anxiety (scale 0–21) 10.1 (4.6) 9.5 (4.6) 0.6 (0.9 to 0.3) <0.001
HADS depression (scale 0–21) 9.6 (4.1) 7.9 (4.5) 1.6 (1.9 to 1.4) <0.001
Visual Analogue Pain (scale 0–100) 47.3 (26.6) 42.0 (28.4) 5.3 (7.0 to 3.6) <0.001
aStudent’s paired t-test
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anxiety, depression and pain) was associated with
fatigue at 8–20 months in models that were only
adjusted for centre and year of assessment
(Table 3). In a model that was adjusted for all base-
line measures, fatigue, physical function and pain,
but not anxiety or depression scores, were asso-
ciated with fatigue at 8–20 months. Similarly, older
age, physical function and pain, were associated
with physical function at 8–20 months. There was
little evidence that anxiety and depression were
associated with physical function at follow-up
(Table 4).
In fully adjusted regression models, each baseline
measure was associated with its repeat measure-
ment at follow-up (Table 5). Lower physical function
at baseline was associated with higher levels of de-
pression and pain at follow-up. Higher levels of pain
at baseline were associated with higher levels of
anxiety and depression at follow-up. Female sex
was associated with lower HADS depression at
follow-up. Higher levels of pain at follow-up were
related to higher levels of baseline fatigue, physical
function and depression (Table 5).
Duration of illness was inversely associated with
baseline physical function [mean change in SF-36
score 0.03; 95% confidence interval (CI) 0.05 to
0.01; P=0.01] per additional month of illness) and
associated with baseline pain (mean change in
visual analogue pain score 0.05; 95% CI 0.02 to
0.07; P=0.001 per additional month of illness),
but was not associated with baseline fatigue or
mood or with any outcomes at 8–20 months in
fully adjusted models.
Service-level factors associated with
treatment outcomes
Including services as a categorical variable in multi-
variable model showed that treatment outcomes
varied between services. Services reported that
they treated patients with CBT, GET, a combination
of both or activity management (Table A1).
Comparing the three services that said they offered
CBT/GET with the three services that only offered
activity management, suggested that patients attend-
ing services offering CBT and GET had less im-
provement in fatigue at 12 months (fully adjusted
coefficient 0.57; 95% CI 0.24 to 0.90;
P=0.001,corresponding to a difference of 2
points on the Chalder Fatigue Scale). However,
this effect mainly represented a comparison be-
tween two large services which assessed 372
(CBT/GET) and 501 (only activity management) pa-
tients, respectively, in 2010.
Discussion
This is the first study to investigate treatment out-
comes and their predictors in patients treated by
more than one NHS specialist CFS/ME service.
Among the patients for whom follow-up data were
available (51% of patients assessed), there were
overall improvements in fatigue, physical function,
anxiety, depression and pain at 12-month
follow-up. As may be expected, the measurement
of each of these symptoms at baseline predicted its
subsequent value when repeated between 8 and 20
months. Patients who were less physically able at
assessment had higher levels of fatigue, depression
and pain at follow-up. Patients who were in more
pain when assessed at baseline had worse scores for
all outcomes at follow-up. There was little evidence
that anxiety or depression was associated with either
fatigue or physical function at follow-up. The size of
improvement in fatigue was similar to that achieved
in the PACE trial after CBT and GET, but this was not
the case for physical function, where the improve-
ment was considerably less in clinical services com-
pared with the PACE trial.
Strengths and limitations
This is a large study with follow-up data on more
than 800 patients with clinically characterized CFS.
Six clinical services contributed to the outcome
data, suggesting that the results are generalizable
to other NHS specialist CFS/ME services which pro-
vide similar types of treatment. However, as the
study was based on data from patients accessing
specialist services, the results may not be general-
izable to patients who receive similar treatments in
primary care. The main limitation of this study is its
relatively low follow-up rate. Compared with pa-
tients who did not complete follow-up, those who
did had similar baseline levels of fatigue, physical
function, pain and mood and similar time-to-
assessment, but were slightly younger. However,
we don’t know whether patients lost to follow-up
had better, the same or worse outcomes at 8–20
months, or how any such differential losses might
affect results. We used 0.5 SD to define the
clinically important difference. Although this is
likely to be close to what patients define as clinically
important,23 further work needs to be done to define
how much change is important to patients and what
outcomes are relevant.
Services completed questionnaires about the type
of treatment offered to patients, but patient-level
treatment data were not collected by the NOD
and therefore we cannot be certain what was pro-
vided. Similarly, services provided estimates of the
Outcomes of treatment of chronic fatigue syndrome in England 559
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number of treatment hours received by patients, but
this was not checked with hospital-level activity
data. A meta-analysis of CBT and GET for CFS
found that total treatment hours were one of the
strongest predictors of outcome.16 The lack of
patient-level treatment data and a non-intervention
group does not allow us to compare treatments or to
determine whether observed improvements were
due to the interventions themselves. Although our
analyses suggested that patients who received activ-
ity management did better than those who received
CBT and/or GET, this was based on a comparison
between three services offering activity management
only and three services offering CBT/GET only. As
one service in each group was much larger than the
others, our result is based on a comparison between
two services. As treatment content and adherence
were not assessed, it is not known whether CBT or
GET conformed to existing protocols or whether ac-
tivity management provided content consistent with
CBT or GET principles. There are many other
service-level factors that could affect outcome be-
tween two services, such as the number of sessions
offered by the service, a known predictor of out-
come,16 the overall philosophy of the service, indi-
vidual therapist effects and patient characteristics.24
We only have data on depression and anxiety
from inventories. Patients did not have a psychiatric
interview. The relationship between depression,
anxiety and physical function could be explored fur-
ther using a clinical assessment of depression rather
than self-report questionnaire scores.
Comparison with previous literature
Baseline measures of fatigue and physical function
in our study were very similar to the PACE trial. The
mean change in fatigue in our study was 6.8 points
(95% CI 7.4 to 6.2), which is consistent with
results from the recently reported PACE trial,
where the mean change in fatigue was 7.4 points
in the CBT group.25 This is in contrast with one pre-
vious study, which showed that improvement in fa-
tigue was greater in trial participants.14 However, in
our study, the mean improvement on the SF-36
physical function subscale was much less [4.4
points (95% CI 3.0 to 5.8)] than in the PACE trial
where the mean improvement was 19.2 points in the
CBT arm and 21.0 in the GET arm. This remarkable
discrepancy suggests that the poor outcome in phys-
ical function in our study may be due to differences
in the delivery or content of treatments given in rou-
tine clinical practice. For example, most patients in
NHS services appear to be offered five or six ses-
sions (Table A1), whereas PACE trial participants
attended 12–14 sessions. This needs urgent
investigation.
Treatments in our study also appear to be less ef-
fective than in other randomized controlled trials
comparing either CBT or GET with controls.16,26.
Patients enrolled in randomized controlled trials
can have better results than seen in clinical practice
because trial clinicians follow a research protocol
and may have more training, supervision, motiv-
ation and resources available to them.14 Trials also
increase expectation of efficacy and patients may be
more motivated.27 Trials usually have selection cri-
teria exceeding those in routine care (e.g. excluding
for significant risk of self-harm or co-morbid medical
conditions and only including those willing and able
to attend regular appointments and complete re-
peated questionnaires); it is not known whether
such factors are associated with treatment
outcomes.
Our study showed that older age predicted worse
outcome at follow-up which is consistent with one
previous study.14 There was little evidence that dur-
ation of illness was associated with any outcomes in
a fully adjusted model which is consistent with pre-
vious studies.16,28 We found that poorer baseline
physical functioning was associated with higher
scores on the depression subscale of the Hospital
Anxiety and Depression Scale at follow-up but not
vice versa. This is in contrast with two previous
follow-up studies of a clinical cohort (n=41)29 and
a randomized controlled trial (n=114)28 which sug-
gested that psychiatric co-morbid diagnoses were
associated with a poorer outcome 30. A previous
cross-sectional study suggested that depression par-
tially mediated the relation between fatigue and
physical disability.31 However, this study used a me-
diation analysis, which was inappropriate in situ-
ations where there are unmeasured confounders
for the effect of both the exposure (fatigue) and the
intermediate (depression) on the outcome (physical
function).32 In chronic fatigue, the relationship be-
tween depression and fatigue is complex,33 and the
relationship with disability is likely to have unmeas-
ured confounders. This aspect of CFS/ME requires
further investigation using longitudinal data that
will allow causality to be determined.
Conclusions
Although NHS services are moderately effective in
improving fatigue in patients with chronic fatigue
syndrome, they are much less effective in improving
physical function than similar treatments delivered
in the PACE trial. This requires urgent investigation
to determine whether it is due to differences in the
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delivery or the content of treatments offered by ser-
vices. Future research also needs to include patient-
level treatment data to investigate variations in out-
come that may be related to treatment data. We did
not find that depression, anxiety or duration of ill-
ness at assessment predicted outcome. Clinicians
providing assessments should not assume that
co-morbid mood disorders or length of illness are
predictors of outcome.
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